Arturo Molina, MD, MS

Dr. Arturo Molina is a distinguished hematologist/oncologist with an extensive background in clinical research and drug development. He currently holds the position of Chief Medical Officer at Protagonist Therapeutics, where he joined in November 2022.12 In addition to this role, Dr. Molina maintains an Adjunct Clinical Professor appointment in the Department of Medicine, Division of Oncology at Stanford University School of Medicine.14

Professional Experience

Dr. Molina's career spans several notable positions in the pharmaceutical and biotechnology industries:

• Chief Medical Officer at Sutro Biopharma (2016-2022)3
• Vice President of Oncology Scientific Innovation at Johnson & Johnson (2013-2016)3
• Chief Medical Officer at Cougar Biotechnology (acquired by Johnson & Johnson in 2009)1

Academic Background

Dr. Molina's educational credentials include:

• M.D. and M.S. in physiology from Stanford University Medical Center
• B.A. in psychology and B.S. in zoology from the University of Texas at Austin1

Research and Clinical Experience

From 1991 to 2002, Dr. Molina served as a faculty staff physician in the Department of Hematology/Bone Marrow Transplantation and Department of Medical Oncology/Therapeutics Research at City of Hope Comprehensive Cancer Center.1 He has also been involved in various clinical development programs, including leading the Abiraterone Acetate (Zytiga) Clinical Program, which resulted in approvals in over 70 countries.3

Additional Roles and Recognitions

• President of Stanford Medicine Alumni Association (2019-2021)3
• National Advisory Committee Member for the Harold Amos Medical Faculty Development Program3
• Recipient of several awards, including the Clinical Vignette Competition Award from the American College of Physicians3

Dr. Molina's expertise in hematology/oncology, combined with his experience in drug development and clinical research, makes him a valuable asset in both academic and industry settings. His ongoing affiliation with Stanford University School of Medicine allows him to contribute to the education and mentorship of future medical professionals while advancing the field of oncology.